Skin Cancer

Personalized Dendritic Cell Vaccination Safe, but More Research Needed on Efficacy

October 21st 2021, 9:31pm


Autologous tumor lysate particle-loaded dendritic cell (TLPLDC) vaccination is well-tolerated in combination with other immunotherapies, but further research is needed to confirm its efficacy.

Rise in Keratinocyte Carcinomas Cause for Concern

October 16th 2021, 1:00pm


New retrospective research found that basal and squamous cell cancers increased by 30% over 15 years.

Brisk Tumor-Infiltrating Lymphocytes May Hold Prognostic Value in Primary Cutaneous Melanoma

October 14th 2021, 2:00pm


A large cohort study aimed to find out whether tumor-infiltrating lymphocytes, an important biomarker in melanoma, could be an independent prognostic factor for overall survival.

Axitinib Plus Anti-PD1 Regimen Is Effective as First-line Mucosal Melanoma Treatment

October 9th 2021, 4:40pm


A retrospective study on the combination of a vascular endothelial growth factor receptor inhibitor plus programmed cell death-1 blockade added to evidence of efficacy in early trials.

Dr Christine Ko on Making Tough Skin Cancer–Related Decisions for Transplant Patients

October 4th 2021, 8:25pm


Christine Ko, MD, professor of dermatology and pathology at Yale University, who specializes in transplant dermatology, explains the considerations involved with skin cancer–related treatment decisions among patients who’ve undergone a solid-organ or other type of organ transplant.

Liquid Biopsy, Radiological Response Predict Posttreatment Outcomes in BRAF-Mutated Melanoma

October 1st 2021, 11:00pm


In patients with BRAF-mutated melanoma, achieving a complete response and circulating tumor DNA negativity are promising prognostic markers.

Dr Todd Schlesinger: Tissue-Sparing Mohs Surgery Is Highly Accurate

September 28th 2021, 2:30pm


Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas, explains the process of Mohs surgery for removing skin cancers and preserving healthy surrounding tissue.

CDK4/6 Targeting May Be Effective in Acquired BRAF Plus MEK Inhibitor–Resistant Melanoma

September 25th 2021, 12:00pm


Combination CDK4/6 and MEK inhibitor treatment reduced tumor growth in mouse models of melanoma with acquired resistance to BRAF and MEK inhibition.

Trial Confirms Clinical Activity of Trametinib Plus Dabrafenib in BRAF-V600–Mutant Melanoma

September 24th 2021, 5:00pm


The largest known prospective study of patients treated with trametinib plus dabrafenib for unresectable advanced melanoma with BRAF-V600 mutation confirmed the combination’s clinical activity.

Care Utilization, Costs Significantly Differ Between First-line Metastatic Melanoma Treatments

September 17th 2021, 12:20pm


A study of patients given first-line metastatic melanoma treatment showed that utilization rates were highest in patients using ipilimumab-containing therapies.